Published in Rinsho Ketsueki on October 01, 2014
A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res (2005) 11.02
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22
AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med (2004) 4.00
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol (2004) 2.28
Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell (2008) 2.05
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood (2013) 2.03
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci (2009) 1.95
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood (2009) 1.78
Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell (2012) 1.78
Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood (2011) 1.65
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. Am J Hematol (2010) 1.46
Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies. Leuk Lymphoma (2013) 1.44
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res (2012) 1.42
Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations. Leuk Res (2006) 1.42
Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma (2010) 1.41
Central nervous system relapse in patients with diffuse large B-cell lymphoma: analysis of incidence and prognostic factors. Leuk Lymphoma (2014) 1.39
Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood (2011) 1.37
Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med (2011) 1.36
Highly efficient ex vivo expansion of human hematopoietic stem cells using Delta1-Fc chimeric protein. Stem Cells (2006) 1.35
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood (2012) 1.29
Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood (2010) 1.29
Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem (2003) 1.25
Evaluation of genome-wide power of genetic association studies based on empirical data from the HapMap project. Hum Mol Genet (2007) 1.25
AML1/Runx1 negatively regulates quiescent hematopoietic stem cells in adult hematopoiesis. J Immunol (2008) 1.24
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest (2013) 1.20
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol (2009) 1.19
The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol Cell Biol (2004) 1.16
Derivation of functional mature neutrophils from human embryonic stem cells. Blood (2009) 1.15
Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res (2009) 1.13
Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol (2008) 1.13
AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. Blood (2006) 1.13
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest (2014) 1.11
A role for RUNX1 in hematopoiesis and myeloid leukemia. Int J Hematol (2013) 1.09
Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol (2005) 1.08
Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle (2004) 1.07
Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis. Pigment Cell Melanoma Res (2008) 1.06
Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Sci (2005) 1.05
Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance. J Immunol (2005) 1.05
FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy. Leuk Res (2010) 1.05
Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.03
Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood (2011) 1.01
Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol (2008) 1.01
Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene (2005) 1.00
AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem (2004) 1.00
Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci (2009) 1.00
The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells. J Cell Physiol (2010) 0.99
Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization. Genes Chromosomes Cancer (2006) 0.97
Essential roles of VLA-4 in the hematopoietic system. Int J Hematol (2010) 0.96
Notch activation induces the generation of functional NK cells from human cord blood CD34-positive cells devoid of IL-15. J Immunol (2009) 0.96
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood (2014) 0.96
Expression profiling of immature thymocytes revealed a novel homeobox gene that regulates double-negative thymocyte development. J Immunol (2007) 0.96
Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone. Arch Neurol (2008) 0.94
Leukemia-related transcription factor TEL is negatively regulated through extracellular signal-regulated kinase-induced phosphorylation. Mol Cell Biol (2004) 0.94
Evi-1 as a critical regulator of leukemic cells. Int J Hematol (2010) 0.94
Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol (2008) 0.94
ESHAP therapy effective in a patient with Langerhans cell sarcoma. Int J Hematol (2008) 0.93
Down-regulation of Runx1 expression by TCR signal involves an autoregulatory mechanism and contributes to IL-2 production. J Biol Chem (2011) 0.93
Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells. Proc Natl Acad Sci U S A (2003) 0.93
AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood (2011) 0.92
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol (2011) 0.92
The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood (2004) 0.92
Functional domains of Runx1 are differentially required for CD4 repression, TCRbeta expression, and CD4/8 double-negative to CD4/8 double-positive transition in thymocyte development. J Immunol (2005) 0.92
Temozolomide may induce therapy-related acute lymphoblastic leukaemia. Br J Haematol (2011) 0.92
Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling. Cancer Sci (2008) 0.92
Structure and function of cas-L and integrin-mediated signaling. Crit Rev Immunol (2006) 0.92
Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol (2011) 0.92
Coordinated regulation of transcription factors through Notch2 is an important mediator of mast cell fate. Proc Natl Acad Sci U S A (2008) 0.91
Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. Intern Med (2012) 0.90
Key roles of histone methyltransferase and demethylase in leukemogenesis. J Cell Biochem (2011) 0.90
The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol (2007) 0.89
The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement. Leuk Res (2011) 0.89
Runx1 deficiency in CD4+ T cells causes fatal autoimmune inflammatory lung disease due to spontaneous hyperactivation of cells. J Immunol (2012) 0.89
T cell acute lymphoblastic leukemia arising from familial platelet disorder. Int J Hematol (2010) 0.88
Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy. Br J Haematol (2011) 0.88
Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Am J Hematol (2003) 0.88
Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc Natl Acad Sci U S A (2011) 0.88
Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Cancer Sci (2012) 0.87
A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia. Int J Hematol (2013) 0.87
CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma (2006) 0.87
The effect of iron overload and chelation on erythroid differentiation. Int J Hematol (2011) 0.87
Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol (2008) 0.86
Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia. Ann Hematol (2008) 0.86
Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS). Ann Hematol (2012) 0.86
Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Sci (2009) 0.86
Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk (2013) 0.86
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion. Int J Hematol (2013) 0.86
Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res (2012) 0.86
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system. CNS Neurol Disord Drug Targets (2009) 0.85
Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.85
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol (2007) 0.85
Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. Am J Hematol (2007) 0.85
Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget (2011) 0.84
Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. Ann Hematol (2010) 0.84
False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother (2007) 0.84
Hyperbilirubinemia after hematopoietic stem cell transplantation: comparison of clinical and pathologic findings in 41 autopsied cases. Clin Transplant (2011) 0.84
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. J Med Virol (2008) 0.84